ArticlePloS one2024
Comparison of journal and top publisher self-citation rates in COVID-19 research.
Article in PloS one, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionJournal self-citation contributes to the overall citation count of a journal and to some metrics like the impact factor. However, little is known about the extent of journal self-citations in COVID-19 research. This study aimed to determine the journal self-citations in COVID-19 research and to compare them according to the type of publication and publisher.
methodsData in COVID-19 research extracted from the Web of Science Core Collection 2020-2023 was collected and further analyzed with InCites. The journals with the highest self-citation rates and self-citation per publication were identified. Statistical comparisons were made according to the type of publication and publishers, as well as with other major infectious diseases.
resultsThe median self-citation rate was 4.0% (IQR 0-11.7%), and the median journal self-citation rate was 5.9% (IQR 0-12.5%). 1,859 journals (13% of total coverage) had self-citation rates at or above 20%, meaning that more than one in five references are journal self-citations. There was a positive and statistically significant correlation of self-citations with the other indicators, including number of publications, citations, and self-citations per publication (p<0.001). Editorial materials contributed more to journal SC with a median self-citation rate of 5%, which was statistically higher than other documents such as articles, letters or reviews (p<0.001). Among the top twelve publishers, the Multidisciplinary Digital Publishing Institute had a median self-citation rate of 8.33% and was statistically higher than the rest (p<0.001). Self-citation rates for COVID-19 were lower than tuberculosis and HIV/AIDS, but self-citations per publication of these diseases were statistically lower than those for COVID-19 (p<0.001).
conclusionSome journals from the Web of Science Core Collection displayed exorbitant journal self-citation patterns during the period 2020-2023. Approximately, one in every five paper references in COVID-19 is a journal self-citation. Types of publication such as editorials engage in this practice more frequently than others, suggesting that in COVID-19 research, self-citing non-citable items could potentially contribute to inflate journal impact factors during the pandemic.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.